Skip to Main Content

Advertisement

American Association for Cancer Research Logo Open Menu
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 12, Issue 6
1 June 2013
Molecular Cancer Therapeutics Cover Image for Volume 12, Issue 6
All Issues
  • Cover Image

    Cover Image

    Issue cover image
    Composite immunofluorescence of HER2-positive human tumor (BT474 M1) xenografts. Tumor sections from mice treated with saline (controls) were stained for tumor cell nuclei (blue) using Hoechst 33342 dye and blood vessels were stained (red) using anti-mouse CD31 antibody. Tumors from the group treated with fusion construct showed tumor-specific delivery of human granzyme B and upregulation of TUNEL-positive tumor cells compared with controls. For details, see article by Cao and colleagues on page 979.
  • PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514

Highlights

Highlights of This Issue
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Open the PDF for in another window

Reviews

Endoplasmic Reticulum Stress and the Unfolded Protein Response: Targeting the Achilles Heel of Multiple Myeloma
Lisa Vincenz; Richard Jäger; Michael O'Dwyer; Afshin Samali
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Open the PDF for in another window
Cyclooxygenase-2, Epidermal Growth Factor Receptor, and Aromatase Signaling in Inflammation and Mesothelioma
Barbara Nuvoli; Rossella Galati
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Open the PDF for in another window

Chemical Therapeutics

Author Choice
Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Nguyen Tan; Maureen Wong; Michelle A. Nannini; Rebecca Hong; Leslie B. Lee; Stephen Price; Karen Williams; Pierre Pascal Savy; Peng Yue; Deepak Sampath; Jeffrey Settleman; Wayne J. Fairbrother; Lisa D. Belmont
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
Ahrum Min; Seock-Ah Im; Young-Kwang Yoon; Sang-Hyun Song; Hyun-Jin Nam; Hyung-Seok Hur; Hwang-Phill Kim; Kyung-Hun Lee; Sae-Won Han; Do-Youn Oh; Tae-You Kim; Mark J. O'Connor; Woo-Ho Kim; Yung-Jue Bang
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
The Novel Chk1 Inhibitor MK-8776 Sensitizes Human Leukemia Cells to HDAC Inhibitors by Targeting the Intra-S Checkpoint and DNA Replication and Repair
Yun Dai; Shuang Chen; Maciej Kmieciak; Liang Zhou; Hui Lin; Xin-Yan Pei; Steven Grant
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth
Edward B. Garon; Richard S. Finn; Habib Hamidi; Judy Dering; Sharon Pitts; Naeimeh Kamranpour; Amrita J. Desai; Wylie Hosmer; Susan Ide; Emin Avsar; Michael Rugaard Jensen; Cornelia Quadt; Manway Liu; Steven M. Dubinett; Dennis J. Slamon
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
Inhibition of Wee1, AKT, and CDK4 Underlies the Efficacy of the HSP90 Inhibitor XL888 in an In Vivo Model of NRAS-Mutant Melanoma
H. Eirik Haarberg; Kim H.T. Paraiso; Elizabeth Wood; Vito W. Rebecca; Vernon K. Sondak; John M. Koomen; Keiran S.M. Smalley
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
A Novel Inhibitor of c-Met and VEGF Receptor Tyrosine Kinases with a Broad Spectrum of In Vivo Antitumor Activities
Yoshiko Awazu; Kazuhide Nakamura; Akio Mizutani; Yuichi Kakoi; Hidehisa Iwata; Seiji Yamasaki; Naoki Miyamoto; Shinichi Imamura; Hiroshi Miki; Akira Hori
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
Author Choice
Potential Advantages of CUDC-101, a Multitargeted HDAC, EGFR, and HER2 Inhibitor, in Treating Drug Resistance and Preventing Cancer Cell Migration and Invasion
Jing Wang; Natalie W. Pursell; Maria Elena S. Samson; Ruzanna Atoyan; Anna W. Ma; Abdelkader Selmi; Wanlu Xu; Xiong Cai; Maurizio Voi; Pierre Savagner; Cheng-Jung Lai
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
Discovery of a Novel Orally Active Small-Molecule gp130 Inhibitor for the Treatment of Ovarian Cancer
Shili Xu; Fedora Grande; Antonio Garofalo; Nouri Neamati
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
Discovery of the Novel mTOR Inhibitor and Its Antitumor Activities In Vitro and In Vivo
Hua Xie; Mee-Hyun Lee; Feng Zhu; Kanamata Reddy; Zunnan Huang; Dong Joon Kim; Yan Li; Cong Peng; Do Young Lim; Soouk Kang; Sung Keun Jung; Xiang Li; Haitao Li; Weiya Ma; Ronald A. Lubet; Jian Ding; Ann M. Bode; Zigang Dong
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Open the PDF for in another window
Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer
Michael A. Batey; Yan Zhao; Suzanne Kyle; Caroline Richardson; Andrew Slade; Niall M.B. Martin; Alan Lau; David R. Newell; Nicola J. Curtin
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Open the PDF for in another window

Large Molecule Therapeutics

Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
Serengulam V. Govindan; Thomas M. Cardillo; Robert M. Sharkey; Fatma Tat; David V. Gold; David M. Goldenberg
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
Construction and Characterization of Novel, Completely Human Serine Protease Therapeutics Targeting Her2/neu
Yu Cao; Khalid A. Mohamedali; John W. Marks; Lawrence H. Cheung; Walter N. Hittelman; Michael G. Rosenblum
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Open the PDF for in another window

Cancer Therapeutics Insights

BIBF 1120 (Nintedanib), a Triple Angiokinase Inhibitor, Induces Hypoxia but not EMT and Blocks Progression of Preclinical Models of Lung and Pancreatic Cancer
Bercin Kutluk Cenik; Katherine T. Ostapoff; David E. Gerber; Rolf A. Brekken
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
Therapeutic Potential of the Poly(ADP-ribose) Polymerase Inhibitor Rucaparib for the Treatment of Sporadic Human Ovarian Cancer
Maike Ihnen; Christine zu Eulenburg; Teodora Kolarova; Jing Wei Qi; Kanthinh Manivong; Meenal Chalukya; Judy Dering; Lee Anderson; Charles Ginther; Alexandra Meuter; Boris Winterhoff; Siân Jones; Victor E. Velculescu; Natarajan Venkatesan; Hong-Mei Rong; Sugandha Dandekar; Nitin Udar; Fritz Jänicke; Gerrit Los; Dennis J. Slamon; Gottfried E. Konecny
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
Author Choice
Downregulation of Hepatoma-Derived Growth Factor Contributes to Retarded Lung Metastasis via Inhibition of Epithelial–Mesenchymal Transition by Systemic POMC Gene Delivery in Melanoma
Han-En Tsai; Guei-Sheung Liu; Mei-Lang Kung; Li-Feng Liu; Jian-Ching Wu; Chia-Hua Tang; Ching-Hui Huang; San-Cher Chen; Hing-Chung Lam; Chieh-Shan Wu; Ming-Hong Tai
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals
Xiaohai Wang; Soo Ok Lee; Shujie Xia; Qi Jiang; Jie Luo; Lei Li; Shuyuan Yeh; Chawnshang Chang
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
Combining Hedgehog Signaling Inhibition with Focal Irradiation on Reduction of Pancreatic Cancer Metastasis
Dongsheng Gu; Hailan Liu; Gloria H. Su; Xiaoli Zhang; Helen Chin-Sinex; Helmut Hanenberg; Marc S. Mendonca; Harlan E. Shannon; E. Gabriela Chiorean; Jingwu Xie
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
Hrk Mediates 2-Methoxyestradiol–Induced Mitochondrial Apoptotic Signaling in Prostate Cancer Cells
Inik Chang; Shahana Majid; Sharanjot Saini; Mohd S. Zaman; Soichiro Yamamura; Takeshi Chiyomaru; Varahram Shahryari; Shinichiro Fukuhara; Guoren Deng; Rajvir Dahiya; Yuichiro Tanaka
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
SMARCB1/INI1 Genetic Inactivation Is Responsible for Tumorigenic Properties of Epithelioid Sarcoma Cell Line VAESBJ
Monica Brenca; Sabrina Rossi; Erica Lorenzetto; Elena Piccinin; Sara Piccinin; Francesca Maria Rossi; Alberto Giuliano; Angelo Paolo Dei Tos; Roberta Maestro; Piergiorgio Modena
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
Synergistic Anticancer Activity of Arsenic Trioxide with Erlotinib Is Based on Inhibition of EGFR-Mediated DNA Double-Strand Break Repair
Kushtrim Kryeziu; Ute Jungwirth; Mir Alireza Hoda; Franziska Ferk; Siegfried Knasmüller; Claudia Karnthaler-Benbakka; Christian R. Kowol; Walter Berger; Petra Heffeter
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
Suppression of Survivin Induced by a BCR-ABL/JAK2/STAT3 Pathway Sensitizes Imatinib-Resistant CML Cells to Different Cytotoxic Drugs
Stefania Stella; Elena Tirrò; Enrico Conte; Fabio Stagno; Francesco Di Raimondo; Livia Manzella; Paolo Vigneri
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
Bisphosphorylated PEA-15 Sensitizes Ovarian Cancer Cells to Paclitaxel by Impairing the Microtubule-Destabilizing Effect of SCLIP
Xuemei Xie; Chandra Bartholomeusz; Ahmed A. Ahmed; Anna Kazansky; Lixia Diao; Keith A. Baggerly; Gabriel N. Hortobagyi; Naoto T. Ueno
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window

Companion Diagnostics & Cancer Biomarkers

Elevated Cyclin D1 Expression Is Predictive for a Benefit from TPF Induction Chemotherapy in Oral Squamous Cell Carcinoma Patients with Advanced Nodal Disease
Lai-Ping Zhong; Dong-Wang Zhu; William N. William, Jr; Ying Liu; Jie Ma; Cheng-Zhe Yang; Xiao Yang; Li-Zhen Wang; Jiang Li; Jeffrey N. Myers; J. Jack Lee; Chen-Ping Zhang; Zhi-Yuan Zhang
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
HGF as a Circulating Biomarker of Onartuzumab Treatment in Patients with Advanced Solid Tumors
Elicia Penuel; Congfen Li; Vaishali Parab; Luciana Burton; Kyra J. Cowan; Mark Merchant; Robert L. Yauch; Premal Patel; Amy Peterson; Garret M. Hampton; Mark R. Lackner; Priti S. Hegde
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window
ERK Phosphorylation Is Predictive of Resistance to IGF-1R Inhibition in Small Cell Lung Cancer
Rebekah L. Zinn; Eric E. Gardner; Luigi Marchionni; Sara C. Murphy; Irina Dobromilskaya; Christine L. Hann; Charles M. Rudin
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window

Tools and Technologies

Profiling Bortezomib Resistance Identifies Secondary Therapies in a Mouse Myeloma Model
Holly A.F. Stessman; Linda B. Baughn; Aaron Sarver; Tian Xia; Raamesh Deshpande; Aatif Mansoor; Susan A. Walsh; John J. Sunderland; Nathan G. Dolloff; Michael A. Linden; Fenghuang Zhan; Siegfried Janz; Chad L. Myers; Brian G. Van Ness
View articletitled, SCM.SharedControls.Infrastructure.TitleDisplayModel?.Text
Supplementary data
Open the PDF for in another window

Advertisement

Latest News
Outgunning mCRPC with SYNC-T
Cranking Out Bispecific T-Cell Engagers, In Vivo
Spotlighting ER Degraders for HR+/HER2- Breast Cancer
View more recent articles
Breaking
Intravesical Chemotherapy Approved for Bladder Cancer
BioNTech to Acquire CureVac for $1.25 Billion
Kinase Inhibitor Greenlighted for NSCLC
View more recent articles
Research Watch
Analysis of the Gut Microbiome Reveals Biomarkers of Colorectal Cancer
Molecular Residual Disease Precedes Disease-Free Survival Events by Months
Cholesterol Metabolism Dictates Secondary Organ Colonization in Pancreatic Cancer
View more recent articles

NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck.  None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.

  • Online ISSN 1538-8514
  • Print ISSN 1535-7163

AACR Journals

 

 

  • Copyright © 2025 by the American Association for Cancer Research.
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept